PHARMAC will give due consideration to any such request.ĭabigatran is an oral anticoagulant that acts via direct inhibition of thrombin in the blood. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request. To provide feedback, please submit it in writing by Friday, 8 July 2016 to:Īll feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.įeedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. PHARMAC welcomes feedback on this proposal. a price reduction for all strengths of dabigatran (Pradaxa) effective 1 September 2016.listing of idarucizumab (Praxbind), the specific reversal agent for dabigatran, in Part II of Section H of the Pharmaceutical Schedule from 1 September 2016.In summary, this proposal would result in: The proposal includes the listing of idarucizumab for use in DHB hospitals, and price reductions for dabigatran.
0 kommentar(er)
